Corrigendum to "Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?"[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226].

IF 6.9 2区医学 Q1 HEMATOLOGY Blood Reviews Pub Date : 2024-09-06 DOI:10.1016/j.blre.2024.101239

Qiujin Shen, Xiaowen Gong, Yahui Feng, Yu Hu, Tiantian Wang, Wen Yan, Wei Zhang, Saibing Qi, Robert Peter Gale, Junren Chen

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

血液学癌症中的可测量残留疾病（MRD）检测：是大跃进还是走偏路？"[《血液学评论》，2024 年 8 月 9 日，https://doi.org/10.1016/j.blre.2024.101226]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Blood Reviews 医学-血液学

CiteScore

13.80

自引率

1.40%

发文量

期刊介绍： Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.

期刊最新文献

From MGUS to multiple myeloma: Unraveling the unknown of precursor states. Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies. Corrigendum to "Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?"[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226]. Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH.